FAST NEWS: Junshi Biosciences announces A-Share buyback
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) said on Sunday its board has approved a plan to buy back some of its A-shares for up to 58 yuan per…
FAST NEWS: Junshi Bio’s Loss Balloons on High R&D Spending
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced on Monday it expects to report its revenue dropped 64.1% to 1.45 billion yuan ($2.14 billion) last year,…
Recent Articles
RELATED ARTICLES
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG -
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
Missing the Covid boat, Junshi stumbles back to old business
1877.HK 688180.SHG
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
